Biomedical subjects

J A Salvá

Publications and source records attributed to J A Salvá.

At least 19 recordsLinked to original sources

PubMed1993

Skin prolylhydroxylase activity and wound healing.

The relationship between wound healing and skin prolylhydroxylase activity was examined in 212 patients undergoing reconstructive procedures and 109 controls using skin prolylhydroxylase activity as an index of collagen synthesis. In the control group, the median value of skin prolylhydroxylase activity was 360 cpm/mg protein. There was a higher skin prolylhydroxylase activity in 274 patients with successful healing (368 cpm/mg protein) than there was in 33 patients who required local wound care (202 cpm/mg protein) and 14 patients with severe local complications (71 cpm/mg protein, p = 0.02). Skin prolylhydroxylase activity was also significantly lower (p = 0.002) in patients with laboratory criteria for malnutrition (albumin < 3.5 g/dl, 108 cpm/mg protein; total lymphocyte count < 1,500 mm3, 211 cpm/mg protein, and albumin < 3.5 g/dl + lymphocyte count < 1,500 mm3, 52 cpm/mg protein), but age, diabetes mellitus, malignancy and wound infection did not affect skin prolylhydroxylase activity. These results suggest that skin prolylhydroxylase activity is reduced in patients with malnutrition and delayed wound healing.

Adolescent↗

PubMed1991

Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage.

Eighty-two consecutive Child-Campbell class A and B cirrhotic patients were included in a prospective controlled trial to assess the efficacy and safety of portacaval anastomosis vs. endoscopic sclerotherapy as elective treatment of variceal hemorrhage. Forty-one patients were randomized to portacaval anastomosis and 41 to sclerotherapy. After excluding dropouts, 34 patients were treated with portacaval anastomosis and 35 with sclerotherapy. The incidence of variceal rebleeding during follow-up (mean +/- SD, 20.6 +/- 14.2 months) was significantly higher in the sclerotherapy than in the portacaval groups, either considering the overall treated group or only patients completing sclerotherapy (40% and 25% vs. 2.9%; P = 0.0002 and P = 0.01, respectively). The 2-year probability of suffering from at least one episode of hepatic encephalopathy was significantly higher in patients submitted to portacaval anastomosis than in those treated with endoscopic sclerotherapy (40% vs. 12%; P = 0.04). However, disabling encephalopathy only appeared in 3 of 34 patients who underwent surgery (8.8%). Early and long-term mortality did not differ between the therapeutic groups; 2-year survival rates were 83% for portacaval anastomosis and 79% for sclerotherapy. It is concluded that portacaval anastomosis is more effective than endoscopic sclerotherapy in preventing variceal rebleeding in spite of the greater incidence of hepatic encephalopathy. The role of portacaval anastomosis in the elective treatment of variceal rebleeding should be reassessed.

Adult↗

PubMed1991

[Gigantic diverticulum of the colon. A complication of diverticulosis?].

We present a patient affected of diverticular disease of the colon, with diverticulosis and two giant diverticula of the sigma, both located at the mesenteric edge. We would like to stress the low incidence of reports about this entity in the medical literature, its uncommon location and the fact of a double lesion coinciding in a single patient. We discuss the most important nosocomial aspects and the different diagnoses. Finally, we support the idea of distinguishing three different entities that in the medical literature are usually unified as a single "giant diverticulum of the colon". We reaffirm ourselves on the importance of an early diagnosis and a correct indication for surgery.

Aged↗

PubMed1989

[Cellular localization, half-life, and secretion of peptide YY].

Tissue and plasma concentration of peptide YY (PYY) were measured by means of a radioimmunoassay (RIA) developed in our laboratory, using a specific PYY antiserum generated in New Zealand white rabbits against synthetic PYY, and dextran-coated charcoal to terminate the assay. Cellular localization of PYY was studied immunohistochemically using the peroxidase-antiperoxidase (PAP) technique. The highest tissue concentration of PYY was found in the mucosa of the terminal ileum and colon. PYY-containing secretory granules were primarily found in the basal pole of open-type endocrine cells. Basal plasma concentration of PYY was 70 +/- 9 pg/ml and rose to 357 +/- 30 pg/ml during the IV administration of PYY at 400 pmol/kg-h. A significant correlation was found (r = 0.94, p less than 0.05) between dose of PYY (12.5, 25, 50, 100, 200, 400 pmol/kg-h, IV) and plasma concentration of PYY. The calculated half-life of PYY in plasma was 8.3 +/- 1.9 minutes. Plasma concentration of PYY during the intraduodenal administration of sodium oleate (150 +/- 20 pg/ml) or long-chain triglyceride (187 +/- 37 pg/ml) was similar to plasma concentration of PYY obtained during the IV administration of PYY at 100 pmol/kg-h. Plasma concentration of PYY raised (126 +/- 10 pg/ml) after the administration of bombesin (400 pmol/kg-h, IV). Bile enhanced release of PYY. The present study suggests a hormonal role for PYY.

Amino Acids↗

PubMed1988